Symbols / QURE
QURE Chart
About
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.48B |
| Enterprise Value | 1.33B | Income | -235.15M | Sales | 15.75M |
| Book/sh | 3.68 | Cash/sh | 11.14 | Dividend Yield | — |
| Payout | 0.00% | Employees | 209 | IPO | — |
| P/E | — | Forward P/E | -7.24 | PEG | — |
| P/S | 94.04 | P/B | 6.46 | P/C | — |
| EV/EBITDA | -8.64 | EV/Sales | 84.71 | Quick Ratio | 6.94 |
| Current Ratio | 7.12 | Debt/Eq | 232.43 | LT Debt/Eq | — |
| EPS (ttm) | -4.40 | EPS next Y | -3.28 | EPS Growth | — |
| Revenue Growth | 61.80% | Earnings | 2026-03-02 | ROA | -13.89% |
| ROE | -165.27% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -13.30% | Profit Margin | 0.00% | Shs Outstand | 62.29M |
| Shs Float | 48.99M | Short Float | 18.51% | Short Ratio | 6.31 |
| Short Interest | — | 52W High | 71.50 | 52W Low | 7.76 |
| Beta | 0.67 | Avg Volume | 2.26M | Volume | 586.57K |
| Target Price | $53.12 | Recom | Buy | Prev Close | $24.03 |
| Price | $23.78 | Change | -1.04% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$53.16
Mean price target
2. Current target
$23.82
Latest analyst target
3. DCF / Fair value
$-21.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$23.82
Low
$30.59
High
$96.94
Mean
$53.16
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | init | Wolfe Research | — → Peer Perform | — |
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $70 |
| 2026-01-28 | init | Barclays | — → Equal-Weight | $31 |
| 2025-12-11 | main | Stifel | Buy → Buy | $40 |
| 2025-12-09 | main | Mizuho | Outperform → Outperform | $33 |
| 2025-12-04 | main | Chardan Capital | Buy → Buy | $53 |
| 2025-11-12 | main | Wells Fargo | Overweight → Overweight | $60 |
| 2025-11-11 | main | Chardan Capital | Buy → Buy | $53 |
| 2025-11-10 | main | Leerink Partners | Outperform → Outperform | $60 |
| 2025-11-04 | main | Goldman Sachs | Neutral → Neutral | $38 |
| 2025-11-04 | main | RBC Capital | Outperform → Outperform | $45 |
| 2025-11-04 | down | William Blair | Outperform → Market Perform | — |
| 2025-11-04 | main | HC Wainwright & Co. | Buy → Buy | $70 |
| 2025-11-03 | main | Chardan Capital | Buy → Buy | $53 |
| 2025-10-06 | main | HC Wainwright & Co. | Buy → Buy | $110 |
| 2025-10-02 | main | Wells Fargo | Overweight → Overweight | $80 |
| 2025-09-25 | main | Goldman Sachs | Neutral → Neutral | $56 |
| 2025-09-25 | main | Mizuho | Outperform → Outperform | $60 |
| 2025-09-25 | main | Wells Fargo | Overweight → Overweight | $65 |
| 2025-09-25 | main | Guggenheim | Buy → Buy | $95 |
- Gene therapy maker uniQure plans March 2 call on 2025 results - Stock Titan Mon, 23 Feb 2026 12
- UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington’s Data Spurs Mizuho Downgrade and Delayed Launch - Yahoo Finance Mon, 15 Dec 2025 08
- Wolfe Research Initiates Coverage of uniQure N.V. (QURE) with Peer Perform Recommendation - Nasdaq ue, 24 Feb 2026 13
- Wolfe Research Initiates Coverage on uniQure (QURE) with 'Peer P - GuruFocus ue, 24 Feb 2026 13
- QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages QURE Investors with Losses to Contact the Firm - Morningstar ue, 24 Feb 2026 23
- $QURE stock is up 7% today. Here's what we see in our data. - Quiver Quantitative ue, 03 Feb 2026 08
- QURE Stock To $500? - Forbes hu, 25 Sep 2025 07
- QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Fri, 20 Feb 2026 19
- Evaluating uniQure (QURE) After New Class Action Allegations Over AMT-130 FDA Disclosures - simplywall.st Mon, 23 Feb 2026 12
- QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - marketscreener.com ue, 24 Feb 2026 22
- Avoiding Lag: Real-Time Signals in (QURE) Movement - Stock Traders Daily hu, 19 Feb 2026 12
- Here’s Why uniQure (QURE) Declined in Q4 - Yahoo Finance Mon, 02 Feb 2026 08
- UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire hu, 19 Feb 2026 13
- FDA to review data on experimental Huntington's gene therapy at uniQure - Stock Titan Fri, 09 Jan 2026 08
- $QURE stock is down 17% today. Here's what we see in our data. - Quiver Quantitative hu, 04 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 25613 | 630483 | — | Sale at price 24.39 - 25.09 per share. | GUT ROBERT | Director | — | 2026-01-12 00:00:00 | D |
| 1 | 17810 | 250765 | — | Conversion of Exercise of derivative security at price 14.08 per share. | GUT ROBERT | Director | — | 2026-01-12 00:00:00 | D |
| 2 | 6390 | 174319 | — | Sale at price 27.28 per share. | KAYE JACK | Director | — | 2026-01-09 00:00:00 | D |
| 3 | 6390 | 123902 | — | Conversion of Exercise of derivative security at price 19.39 per share. | KAYE JACK | Director | — | 2026-01-09 00:00:00 | D |
| 4 | 31434 | 856881 | — | Sale at price 27.22 - 27.30 per share. | GUT ROBERT | Director | — | 2025-11-06 00:00:00 | D |
| 5 | 15840 | 72389 | — | Conversion of Exercise of derivative security at price 4.57 per share. | GUT ROBERT | Director | — | 2025-11-06 00:00:00 | D |
| 6 | 38810 | 1177517 | — | Sale at price 30.33 - 30.36 per share. | KAYE JACK | Director | — | 2025-11-04 00:00:00 | D |
| 7 | 38810 | 383535 | — | Conversion of Exercise of derivative security at price 5.37 - 14.08 per share. | KAYE JACK | Director | — | 2025-11-04 00:00:00 | D |
| 8 | 18000 | 945120 | — | Sale at price 40.04 - 55.00 per share. | KLEMT CHRISTIAN | Chief Financial Officer | — | 2025-09-26 00:00:00 | D |
| 9 | 18000 | 119640 | — | Conversion of Exercise of derivative security at price 5.37 - 13.03 per share. | KLEMT CHRISTIAN | Chief Financial Officer | — | 2025-09-26 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -2.73M | -733.24K | 298.39K | 285.16K |
| TaxRateForCalcs | 0.26 | 0.26 | 0.01 | 0.01 |
| NormalizedEBITDA | -150.16M | -250.26M | -134.05M | 318.08M |
| TotalUnusualItems | -10.58M | -2.84M | 26.04M | 29.50M |
| TotalUnusualItemsExcludingGoodwill | -10.58M | -2.84M | 26.04M | 29.50M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -239.56M | -308.48M | -126.79M | 329.59M |
| ReconciledDepreciation | 12.64M | 11.90M | 8.54M | 7.30M |
| ReconciledCostOfRevenue | 7.80M | 3.78M | 3.34M | 24.98M |
| EBITDA | -160.75M | -253.10M | -108.02M | 347.58M |
| EBIT | -173.39M | -265.00M | -116.56M | 340.28M |
| NetInterestIncome | -42.33M | -22.00M | -11.10M | -7.31M |
| InterestExpense | 63.74M | 41.56M | 11.70M | 7.47M |
| InterestIncome | 21.41M | 19.56M | 609.00K | 162.00K |
| NormalizedIncome | -231.71M | -306.37M | -152.53M | 300.37M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -239.56M | -308.48M | -126.79M | 329.59M |
| TotalExpenses | 209.30M | 298.33M | 250.73M | 212.51M |
| RentExpenseSupplemental | 1.36M | 900.00K | 820.00K | |
| TotalOperatingIncomeAsReported | -184.29M | -282.87M | -143.16M | 310.62M |
| DilutedAverageShares | 48.65M | 47.67M | 46.74M | 46.84M |
| BasicAverageShares | 48.65M | 47.67M | 46.74M | 45.99M |
| DilutedEPS | -4.92 | -6.47 | -2.71 | 7.04 |
| BasicEPS | -4.92 | -6.47 | -2.71 | 7.17 |
| DilutedNIAvailtoComStockholders | -239.56M | -308.48M | -126.79M | 329.59M |
| NetIncomeCommonStockholders | -239.56M | -308.48M | -126.79M | 329.59M |
| NetIncome | -239.56M | -308.48M | -126.79M | 329.59M |
| NetIncomeIncludingNoncontrollingInterests | -239.56M | -308.48M | -126.79M | 329.59M |
| NetIncomeContinuousOperations | -239.56M | -308.48M | -126.79M | 329.59M |
| TaxProvision | 2.43M | 1.92M | -1.47M | 3.22M |
| PretaxIncome | -237.13M | -306.56M | -128.26M | 332.81M |
| OtherIncomeExpense | -12.62M | -2.08M | 27.12M | 28.62M |
| OtherNonOperatingIncomeExpenses | -2.04M | 766.00K | 1.09M | -876.00K |
| SpecialIncomeCharges | -73.00K | -361.00K | 0.00 | |
| GainOnSaleOfBusiness | 1.15M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | 1.22M | 361.00K | 0.00 | |
| GainOnSaleOfSecurity | -10.51M | -2.48M | 26.04M | 29.50M |
| NetNonOperatingInterestIncomeExpense | -42.33M | -22.00M | -11.10M | -7.31M |
| InterestExpenseNonOperating | 63.74M | 41.56M | 11.70M | 7.47M |
| InterestIncomeNonOperating | 21.41M | 19.56M | 609.00K | 162.00K |
| OperatingIncome | -182.18M | -282.49M | -144.25M | 311.49M |
| OperatingExpense | 190.97M | 284.70M | 247.39M | 187.53M |
| OtherOperatingExpenses | -5.60M | -5.29M | -6.08M | -12.31M |
| DepreciationAmortizationDepletionIncomeStatement | 2.11M | 2.05M | 1.18M | |
| DepreciationAndAmortizationInIncomeStatement | 2.11M | 2.05M | 1.18M | |
| DepreciationIncomeStatement | 2.11M | 2.05M | 1.18M | |
| ResearchAndDevelopment | 143.78M | 214.86M | 197.59M | 143.55M |
| SellingGeneralAndAdministration | 50.68M | 73.08M | 54.70M | 56.29M |
| GeneralAndAdministrativeExpense | 50.68M | 73.08M | 54.70M | |
| OtherGandA | 16.05M | 30.39M | 17.33M | |
| RentAndLandingFees | 1.36M | 900.00K | 820.00K | |
| SalariesAndWages | 33.27M | 41.78M | 36.54M | |
| GrossProfit | 8.79M | 2.21M | 103.14M | 499.03M |
| CostOfRevenue | 18.33M | 13.63M | 3.34M | 24.98M |
| TotalRevenue | 27.12M | 15.84M | 106.48M | 524.00M |
| OperatingRevenue | 27.12M | 15.84M | 106.48M | 524.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 48.99M | 47.83M | 46.97M | 46.30M |
| ShareIssued | 48.99M | 47.83M | 46.97M | 46.30M |
| TotalDebt | 66.06M | 138.41M | 142.89M | 135.72M |
| TangibleBookValue | -100.21M | 120.81M | 391.65M | 505.46M |
| InvestedCapital | 44.57M | 309.42M | 578.80M | 696.74M |
| WorkingCapital | 350.24M | 578.18M | 400.86M | 591.48M |
| NetTangibleAssets | -100.21M | 120.81M | 391.65M | 505.46M |
| CapitalLeaseObligations | 14.74M | 36.66M | 40.10M | 34.76M |
| CommonStockEquity | -6.75M | 207.67M | 476.01M | 595.78M |
| TotalCapitalization | 44.57M | 309.42M | 578.80M | 696.74M |
| TotalEquityGrossMinorityInterest | -6.75M | 207.67M | 476.01M | 595.78M |
| StockholdersEquity | -6.75M | 207.67M | 476.01M | 595.78M |
| GainsLossesNotAffectingRetainedEarnings | -52.80M | -53.55M | -58.29M | -28.86M |
| OtherEquityAdjustments | -52.80M | -53.55M | -58.29M | -28.86M |
| RetainedEarnings | -1.13B | -890.41M | -581.93M | -455.14M |
| AdditionalPaidInCapital | 1.17B | 1.15B | 1.11B | 1.08B |
| CapitalStock | 2.94M | 2.88M | 2.84M | 2.80M |
| CommonStock | 2.94M | 2.88M | 2.84M | 2.80M |
| TotalLiabilitiesNetMinorityInterest | 563.29M | 624.02M | 228.96M | 213.40M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 523.24M | 550.34M | 153.04M | 176.64M |
| OtherNonCurrentLiabilities | 453.73M | 412.74M | 10.27M | 33.78M |
| NonCurrentDeferredLiabilities | 7.04M | 7.54M | 8.26M | 12.91M |
| NonCurrentDeferredTaxesLiabilities | 7.04M | 7.54M | 8.26M | 12.91M |
| LongTermDebtAndCapitalLeaseObligation | 62.46M | 130.06M | 134.51M | 129.95M |
| LongTermCapitalLeaseObligation | 11.14M | 28.32M | 31.72M | 28.99M |
| LongTermDebt | 51.32M | 101.75M | 102.79M | 100.96M |
| CurrentLiabilities | 40.05M | 73.67M | 75.92M | 36.76M |
| OtherCurrentLiabilities | 6.53M | 29.65M | 25.98M | |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 3.60M | 8.34M | 8.38M | 5.77M |
| CurrentCapitalLeaseObligation | 3.60M | 8.34M | 8.38M | 5.77M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 12.58M | 16.26M | 17.20M | 12.60M |
| PayablesAndAccruedExpenses | 17.34M | 19.42M | 24.35M | 18.39M |
| CurrentAccruedExpenses | 10.11M | 12.83M | 13.37M | 15.88M |
| Payables | 7.23M | 6.59M | 10.98M | 2.50M |
| AccountsPayable | 7.23M | 6.59M | 10.98M | 2.50M |
| TotalAssets | 556.54M | 831.69M | 704.96M | 809.18M |
| TotalNonCurrentAssets | 166.25M | 179.84M | 228.19M | 180.94M |
| OtherNonCurrentAssets | 1.40M | 3.18M | 6.06M | 5.90M |
| NonCurrentDeferredAssets | 9.86M | 12.28M | 14.53M | 15.65M |
| NonCurrentDeferredTaxesAssets | 9.86M | 12.28M | 14.53M | 15.65M |
| InvestmentsAndAdvances | 27.46M | 2.18M | 39.98M | 0.00 |
| OtherInvestments | 27.46M | 2.18M | ||
| InvestmentinFinancialAssets | 0.00 | 39.98M | 0.00 | |
| HeldToMaturitySecurities | 0.00 | 39.98M | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 93.46M | 86.86M | 84.36M | 90.32M |
| OtherIntangibleAssets | 71.04M | 60.48M | 58.78M | 62.69M |
| Goodwill | 22.41M | 26.38M | 25.58M | 27.63M |
| NetPPE | 34.07M | 75.34M | 83.26M | 69.08M |
| AccumulatedDepreciation | -31.66M | -55.67M | -44.13M | -36.90M |
| GrossPPE | 65.73M | 131.01M | 127.38M | 105.98M |
| Leases | 24.81M | 46.51M | 44.87M | 45.37M |
| ConstructionInProgress | 0.00 | 5.67M | 5.41M | 5.07M |
| OtherProperties | 37.01M | 72.45M | 72.12M | 51.07M |
| MachineryFurnitureEquipment | 3.91M | 6.38M | 4.99M | 4.46M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 390.29M | 651.85M | 476.77M | 628.24M |
| OtherCurrentAssets | 7.61M | 2.65M | 2.81M | 2.67M |
| PrepaidAssets | 9.28M | 15.09M | 11.82M | 10.54M |
| Inventory | 0.00 | 12.02M | 6.92M | 0.00 |
| FinishedGoods | 0.00 | 758.00K | 1.47M | 0.00 |
| WorkInProcess | 0.00 | 4.11M | 1.87M | 0.00 |
| RawMaterials | 0.00 | 7.16M | 3.58M | 0.00 |
| Receivables | 5.88M | 4.19M | 102.38M | 58.77M |
| AccountsReceivable | 5.88M | 4.19M | 102.38M | 58.77M |
| CashCashEquivalentsAndShortTermInvestments | 367.52M | 617.89M | 352.84M | 556.26M |
| OtherShortTermInvestments | 208.59M | 376.53M | 124.83M | 0.00 |
| CashAndCashEquivalents | 158.93M | 241.36M | 228.01M | 556.26M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -194.42M | -153.08M | -162.75M | 270.52M |
| RepaymentOfDebt | -53.05M | 0.00 | 0.00 | -1.57M |
| IssuanceOfDebt | 0.00 | 0.00 | 64.07M | |
| IssuanceOfCapitalStock | 2.12M | 308.00K | 1.45M | 33.70M |
| CapitalExpenditure | -11.69M | -7.15M | -17.69M | -17.44M |
| InterestPaidSupplementalData | 20.57M | 16.88M | 9.25M | 6.54M |
| EndCashPosition | 160.33M | 244.54M | 231.17M | 559.35M |
| BeginningCashPosition | 244.54M | 231.17M | 559.35M | 247.68M |
| EffectOfExchangeRateChanges | -4.97M | 2.27M | -1.83M | -3.76M |
| ChangesInCash | -79.25M | 11.11M | -326.35M | 315.43M |
| FinancingCashFlow | -59.49M | 362.72M | 1.45M | 94.86M |
| CashFlowFromContinuingFinancingActivities | -59.49M | 362.72M | 1.45M | 94.86M |
| NetOtherFinancingCharges | -8.56M | 362.41M | -1.33M | |
| ProceedsFromStockOptionExercised | 2.80M | |||
| NetCommonStockIssuance | 2.12M | 308.00K | 1.45M | 33.70M |
| CommonStockIssuance | 2.12M | 308.00K | 1.45M | 33.70M |
| NetIssuancePaymentsOfDebt | -53.05M | 0.00 | 0.00 | 62.49M |
| NetLongTermDebtIssuance | -53.05M | 0.00 | 0.00 | 62.49M |
| LongTermDebtPayments | -53.05M | 0.00 | 0.00 | -1.57M |
| LongTermDebtIssuance | 0.00 | 0.00 | 64.07M | |
| InvestingCashFlow | 162.97M | -205.69M | -182.73M | -67.39M |
| CashFlowFromContinuingInvestingActivities | 162.97M | -205.69M | -182.73M | -67.39M |
| NetInvestmentPurchaseAndSale | 174.66M | -198.53M | -163.15M | 0.00 |
| SaleOfInvestment | 534.50M | 167.91M | 0.00 | 0.00 |
| PurchaseOfInvestment | -359.84M | -366.44M | -163.15M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -1.90M | -49.95M |
| PurchaseOfBusiness | 0.00 | 0.00 | -1.90M | -49.95M |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | ||
| PurchaseOfIntangibles | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | -11.69M | -7.15M | -17.69M | -17.44M |
| PurchaseOfPPE | -11.69M | -7.15M | -17.69M | -17.44M |
| OperatingCashFlow | -182.73M | -145.93M | -145.06M | 287.96M |
| CashFlowFromContinuingOperatingActivities | -182.73M | -145.93M | -145.06M | 287.96M |
| ChangeInWorkingCapital | -3.94M | 82.44M | -43.38M | -50.48M |
| ChangeInPayablesAndAccruedExpense | -4.12M | -9.50M | 12.62M | 8.48M |
| ChangeInAccruedExpense | -5.64M | -5.33M | 3.38M | 9.20M |
| ChangeInPayable | 1.52M | -4.17M | 9.24M | -727.00K |
| ChangeInAccountPayable | 1.52M | -4.17M | 9.24M | -727.00K |
| ChangeInInventory | 2.42M | -6.74M | -6.92M | 0.00 |
| ChangeInReceivables | -2.24M | 98.68M | -49.08M | -58.96M |
| ChangesInAccountReceivables | -2.24M | -1.32M | -4.08M | -3.96M |
| OtherNonCashItems | 18.93M | 44.32M | 5.92M | 4.04M |
| StockBasedCompensation | 22.26M | 35.09M | 34.20M | 25.64M |
| AmortizationOfSecurities | -10.90M | -10.92M | 0.00 | 0.00 |
| DeferredTax | 2.43M | 1.92M | -1.47M | 3.21M |
| DeferredIncomeTax | 2.43M | 1.92M | -1.47M | 3.21M |
| DepreciationAmortizationDepletion | 12.64M | 11.90M | 8.54M | 7.30M |
| DepreciationAndAmortization | 12.64M | 11.90M | 8.54M | 7.30M |
| Depreciation | 12.64M | 11.90M | 8.54M | |
| OperatingGainsLosses | 15.41M | -2.21M | -22.08M | -31.34M |
| GainLossOnInvestmentSecurities | 6.84M | |||
| NetForeignCurrencyExchangeGainLoss | 15.41M | -2.21M | -22.08M | -31.34M |
| NetIncomeFromContinuingOperations | -239.56M | -308.48M | -126.79M | 329.59M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for QURE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|